DeCure for Immunodeficiency 123 with HPV-related verrucosis
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for immunodeficiency 123 with HPV-related verrucosis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleImmunodeficiency 123 with HPV-related verrucosis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for immunodeficiency 123 with hpv-related verrucosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interleukin 7 (IL7) — IL7 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3DI2 · 2.7 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
In a South African cervical cancer screening trial, 577 women were HIV positive at enrolment, 123 women seroconverted during follow-up, and 4895 remained HIV negative. Among the seroconverters, HPV infection prevalence was 20.3% before seroconversion, 23.6% at seroconversion, and 49.1% after seroconversion. The increase after seroconversion was statistically significant. Seroconverters had significantly lower HPV prevalence than women with established HIV infection before and at seroconversion (41.8% and 45.9%), but after seroconversion their prevalence matched that of women with prevalent HIV infection (49.4%). HIV seroconversion was associated with a fourfold increased hazard of newly detected HPV infection and a 2.5-fold increased hazard of low-grade cytological abnormalities compared with HIV-negative women. The authors concluded that mucosal immune dysfunction early in HIV infection may influence HPV-related disease.
A 1991 review of AIDS and HIV-related conditions noted that multidrug regimens for prophylaxis, acute care, and chronic suppression were usually required, and that management had become standardised. It did not address verrucosis or HPV specifically.
A 2023 paper on systemic retinoids for generalised verrucosis due to congenital immunodeficiency has been retracted. The retracted paper described two cases of generalised verrucosis due to congenital interleukin-7 deficiency treated with systemic retinoids, and a literature review that the authors said suggested systemic retinoids were a safe and effective option for recalcitrant wart lesions. Because the paper is retracted, its findings cannot be relied upon.
What is missing is any controlled trial of retinoids or any other drug for verrucosis in the context of immunodeficiency 123, a condition not named in these abstracts. The HIV data show only that early immune dysfunction increases HPV detection, not that any intervention alters that course. No abstract provides evidence for a specific treatment in immunodeficiency 123 with HPV-related verrucosis. Money for a dedicated trial, a defined patient stratification strategy, and a trial design that accounts for the underlying immunodeficiency are all absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Infectious Diseases · 2011 · 59 citations · open access
Rapid Rise in Detection of Human Papillomavirus (HPV) Infection Soon After Incident HIV Infection Among South African Women
AbstractBACKGROUND: It is well established that the prevalence of human papillomavirus (HPV) infection is increased among human immunodeficiency virus (HIV)-positive individuals, but the temporal relationships between these infections are unclear. METHODS: During a South African cervical cancer screening trial, 5595 women 35-65 years of age were followed up for 36 months; 577 women were HIV positive at enrollment, HIV seroconversion occurred in 123 women, and 4895 women remained HIV negative throughout. Tests for high-risk HPV DNA and cytology were performed on cervical samples, and a colposcopy/biopsy was performed at each visit. The effects of early HIV infection on the risk of HPV infection and HPV-related disease were evaluated. RESULTS: Among seroconverters, HPV infection prevalence was 20.3% before seroconversion, 23.6% at seroconversion (P = .4), and 49.1% after seroconversion (P = .01). Seroconverters had significantly lower HPV infection prevalence than women with prevalent HIV infection before and at seroconversion (41.8% and 45.9%, respectively) but had similar HPV infection prevalence to women with prevalent HIV infection after seroconversion (49.4%). HIV seroconversion was associated with newly detected HPV infection (adjusted hazard ratio [AHR], 4.02; 95% confidence interval [CI], 2.26-7.13) and increased risk of low-grade cytological abnormalities (AHR, 2.53; 95% CI, 1.16-5.51) compared with HIV-negative women. CONCLUSION: Detection of HPV infection increases rapidly within the first years after HIV seroconversion, suggesting that mucosal immune dysfunction occurring at an early stage of HIV infection may influence HPV-related diseases.
AbstractWith about 1 miIlion persons in the US infected with the human immunodeficiency virus (lilV), the inevitable impact of the epidemic on primary care was only a matter of time. That time has come. The majority of family physicians are now caring for patients infected with HN. Providing primary care for patients infected with lllV presents a great challenge. Our understanding of the immunology and pathology of and therapy for lllV infection continues to evolve rapidly. The number of possible opportunistic infections, malignancies, and other complications associated with lllV disease is enormous. Multidrug regimens for prophylaxis, acute care, and chronic suppression are usually required. Providing this complex medical treatment while remaining attentive to the social, psychological, and family components of care is the challenge we must meet. Fortunately, the management of lllV infection has standardized in the last few years. This Current Report-lllV updates treatment recommendations outlined in our earlier review article in JABFP.l Subsequent articles in the series have addressed new developments in managing lllV infection.2-9 A comprehensive review of the dermatologic manifestations of lllV infection supplements these articles. to
RETRACTED: Systemic Retinoids for Generalized Verrucosis Due to Congenital Immunodeficiency: Case Reports and Review of the Literature
AbstractGeneralized verrucosis (GV) is a group of immunodeficiency disorders accompanied by widespread human papillomavirus infection. We revisit two cases of GV due to congenital interleukin-7 deficiency successfully treated with systemic retinoids. We also present a review of the literature on the use of systemic retinoids to treat GV. Our review suggests that systemic retinoids are a safe and effective option for managing recalcitrant wart lesions in cases of GV.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
